Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Herbst

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2019
The Immunoscore: Colon Cancer and BeyondHelen K Angell, Daniela Bruni, J Carl Barrett, et al.
Bioorganic & Medicinal Chemistry Letters|June 2, 2009
Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitorsBrian R Lahue, Yao Ma, Gerald W Shipps, et al.
Molecular Immunology|February 17, 2017
CD47 limits antibody dependent phagocytosis against non-malignant B cellsSandra Gallagher, Sean Turman, Kristen Lekstrom, et al.
European Journal of Clinical Investigation|March 23, 2013
Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune diseaseDonna K Finch, Rachel Ettinger, Jodi L Karnell, et al.
Annual Review of Immunology|March 3, 2010
HMGB1 and RAGE in inflammation and cancerGary P Sims, Daniel C Rowe, Svend T Rietdijk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2016
Loss of Immune Tolerance Is Controlled by ICOS in Sle1 MiceNanette Mittereder, Ellen Kuta, Geetha Bhat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 26, 2015
MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19Sandra Gallagher, Isharat Yusuf, Tom M McCaughtry, et al.
Wellcome Open Research|March 29, 2018
Characterisation of innate lymphoid cell populations at different sites in mice with defective T cell immunityEmma E Dutton, Ana Camelo, Matthew Sleeman, et al.
International Immunopharmacology|May 11, 2016
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic miceSandra Gallagher, Sean Turman, Isharat Yusuf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignanciesRalph F Alderson, Robert J Kreitman, Tianling Chen, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2019
The Immunoscore: Colon Cancer and BeyondHelen K Angell, Daniela Bruni, J Carl Barrett, et al.
Bioorganic & Medicinal Chemistry Letters|June 2, 2009
Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitorsBrian R Lahue, Yao Ma, Gerald W Shipps, et al.
Molecular Immunology|February 17, 2017
CD47 limits antibody dependent phagocytosis against non-malignant B cellsSandra Gallagher, Sean Turman, Kristen Lekstrom, et al.
European Journal of Clinical Investigation|March 23, 2013
Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune diseaseDonna K Finch, Rachel Ettinger, Jodi L Karnell, et al.
Annual Review of Immunology|March 3, 2010
HMGB1 and RAGE in inflammation and cancerGary P Sims, Daniel C Rowe, Svend T Rietdijk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2016
Loss of Immune Tolerance Is Controlled by ICOS in Sle1 MiceNanette Mittereder, Ellen Kuta, Geetha Bhat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 26, 2015
MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19Sandra Gallagher, Isharat Yusuf, Tom M McCaughtry, et al.
Wellcome Open Research|March 29, 2018
Characterisation of innate lymphoid cell populations at different sites in mice with defective T cell immunityEmma E Dutton, Ana Camelo, Matthew Sleeman, et al.
International Immunopharmacology|May 11, 2016
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic miceSandra Gallagher, Sean Turman, Isharat Yusuf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignanciesRalph F Alderson, Robert J Kreitman, Tianling Chen, et al.
Pageof 8